OZETTE
DEAD

Serial Number

97374157

Owner

Ozette Technologies, Inc.

Attorney

Chelsea E. Carbone

Filing Date

Apr 21, 2022

Add to watchlist:

No watchlists yet
View on USPTO

OZETTE Trademark

Serial Number: 97374157

OZETTE is a trademark filed by Ozette Technologies, Inc. on April 21, 2022. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus). The application is currently no longer active.

Owner Contact Info

Ozette Technologies, Inc. (2 trademarks)

18 W Mercer St
Seattle, WA 98119

Entity Type: 03

Trademark Details

Filing Date

April 21, 2022

Registration Date

Not Registered

Published for Opposition

June 27, 2023

Goods & Services

Downloadable computer software using artificial intelligence (AI) and machine learning for analysis of immune data for the purposes of medical research, diagnosis, and treatment; downloadable computer software using artificial intelligence (AI) and machine learning for analysis of immune data for the purposes of identifying, prescribing, and monitoring medications; downloadable computer software using artificial intelligence (AI) and machine learning for diagnosing, monitoring, and treating diseases and disorders, namely, infectious disease, cancer, autoimmune disorders, cardiovascular disease, and neurological disorders; software as a Medical Device (SaMD), downloadable, for analyzing the immune system for the purposes of medical diagnosis and treatment; software as a Medical Device (SaMD), downloadable, for analyzing the immune system for the purposes of identifying, prescribing and monitoring medications; software as a Medical Device (SaMD), downloadable, for diagnosing, monitoring and treating diseases and disorders, namely, infectious disease, cancer, autoimmune disorders, cardiovascular disease, and neurological disorders; computer hardware; computer hardware with imbedded software for diagnosing, monitoring, and treating diseases and disorders, namely, infectious disease, cancer, autoimmune disorders, cardiovascular disease, and neurological disorders; research laboratory analyzers for measuring, testing and analyzing blood and other bodily fluids

Chemical test kits for diagnosing, monitoring, and treating infectious disease, cancer, autoimmune disorders, cardiovascular disease, and neurological disorders for laboratory or research use; assays for research purposes; assays for testing blood and other bodily fluids for research purposes; assays and reagents for use in infectious disease, oncology, autoimmunity, cardiovascular, and neurological disorders research

Medical device for detecting diseases and disorders, namely, infectious disease, cancer, autoimmune disorders, cardiovascular disease, and neurological disorders; medical device, namely, medical device for disease and disorder diagnosis, monitoring of biological material and cell populations, and medical treatment device in the nature of medical devices for the interrogation of biological samples; medical devices for detection and treatment of infectious disease, cancer, autoimmune disorders, cardiovascular disease, and neurological disorders; apparatus for blood analysis; apparatus for taking blood samples; blood collection kit comprised of medical tubes and vials, tube and vial holders, and transportation device and blood testing apparatus; medical apparatus and instrument for diagnostic use, namely, apparatus for medical diagnostic testing in the fields of infectious disease, oncology, autoimmunity, cardiovascular, and neurological disorders; laboratory apparatus, namely, diagnostic apparatus for the interrogation of biological samples featuring artificial intelligence (AI) and machine learning recorded software for medical diagnosis, monitoring, and treatment of diseases and disorders, namely, infectious disease, cancer, autoimmune disorders, cardiovascular disease, and neurological disorders; laboratory apparatus, namely, diagnostic apparatus for the interrogation of biological samples featuring artificial intelligence (AI) and machine learning recorded software for monitoring the immune system for the purposes of identifying, prescribing, and monitoring medications; laboratory apparatus and instruments in the nature of medical devices and diagnostic apparatus for the interrogation of biological samples for diagnosing diseases and disorders, namely, infectious disease, cancer, autoimmune disorders, cardiovascular disease, and neurological disorders

Medical diagnostic reagents and assays for testing and analyzing blood and other bodily fluids; diagnostic kits comprised of medical diagnostic reagents and assays for testing of blood and other bodily fluids for use in disease and disorder detection, namely, infectious disease, cancer, autoimmune disorders, cardiovascular disease, and neurological disorders; pharmaceutical preparations for use in treating infectious disease, cancer, autoimmune disorders, cardiovascular disease, and neurological disorders; drug testing kits comprised of medical diagnostic reagents and assays for testing blood and other bodily fluids; diagnostic reagents for medicinal use

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Mar 30, 2026 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Mar 30, 2026 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 13, 2025 EXRA
SOU EXTENSION 4 GRANTED
Aug 13, 2025 EX4G
SOU TEAS EXTENSION RECEIVED
Aug 11, 2025 EEXT
SOU EXTENSION 4 FILED
Aug 10, 2025 EXT4
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 15, 2025 EXRA
SOU EXTENSION 3 GRANTED
Feb 14, 2025 EX3G
SOU EXTENSION 3 FILED
Feb 12, 2025 EXT3
SOU TEAS EXTENSION RECEIVED
Feb 12, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 14, 2024 EXRA
SOU EXTENSION 2 GRANTED
Aug 14, 2024 EX2G
SOU EXTENSION 2 FILED
Aug 14, 2024 EXT2
SOU TEAS EXTENSION RECEIVED
Aug 14, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 23, 2024 EXRA
CORRECTED NOA E-MAILED
Mar 23, 2024 NOAC
DIVISIONAL PROCESSING COMPLETE
Mar 22, 2024 DPCC
SOU EXTENSION 1 GRANTED
Mar 22, 2024 EX1G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Feb 29, 2024 AITU
DIVISIONAL REQUEST RECEIVED
Feb 6, 2024 DRRR
TEAS REQUEST TO DIVIDE RECEIVED
Feb 6, 2024 ERTD
SOU EXTENSION 1 FILED
Feb 5, 2024 EXT1
SOU TEAS EXTENSION RECEIVED
Feb 5, 2024 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Aug 22, 2023 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 27, 2023 NPUB
PUBLISHED FOR OPPOSITION
Jun 27, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 7, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 25, 2023 CNSA
EXAMINER'S AMENDMENT ENTERED
May 25, 2023 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
May 25, 2023 GNEN
EXAMINERS AMENDMENT E-MAILED
May 25, 2023 GNEA
EXAMINERS AMENDMENT -WRITTEN
May 25, 2023 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
May 24, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 22, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 22, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 23, 2023 GNRN
NON-FINAL ACTION E-MAILED
Feb 23, 2023 GNRT
NON-FINAL ACTION WRITTEN
Feb 23, 2023 CNRT
ASSIGNED TO EXAMINER
Feb 8, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 27, 2022 NWOS
NEW APPLICATION ENTERED
Apr 25, 2022 NWAP